OTIC News and Press, Otonomy Inc. From 02/04/21

SAN DIEGO, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the fourth quarter and full year 2020 and provide a corpo...

OTIC failed a phase 3 trial and fell from $20 to $5, and hasn't recovered since despite succeeding in another phase 3. A tiebreaker third phase 3 is ongoing with data by 1Q2021. If successful, the stock may have a surge. For further details see: Otonomy And Its Efforts A...

SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that management is scheduled to participate in a fireside chat at the virtual H.C. Wainwright ...

Otonomy (OTIC) gains 10% in premarket on the heels of positive top-line results from Phase 1/2 trial evaluating OTO-413 in subjects with speech-in-noise hearing difficulty. Results include the 9 subjects from the OTO-413 high dose (0.3 mg) cohort with test results on both Day 5...

OTO-413 demonstrated a higher proportion of responders than placebo based on multiple speech-in-noise hearing tests A single intratympanic injection of OTO-413 was well-tolerated Otonomy intends to continue clinical development of OTO-413 Management will review...

After review of Otonomy's ([[OTIC]] +0.7%) Otividex statistical analysis plan, the FDA confirms use of the Negative Binomial model for analysis of the primary endpoint in the ongoing Phase 3 trial in Ménière’s disease (inner ear disorder). As previously reported, en...

FDA’s review confirms use of Negative Binomial m odel for analysis of primary endpoint in ongoing OTIVIDEX Phase 3 trial in Ménière’s disease ; results still expected in fir...

Otonomy, Inc. (OTIC) Q3 2020 Earnings Conference Call November 4, 2020 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners, LLC David Weber - President, CEO & Director Paul Cayer - Chief Financial & Business Officer Conference Call Participants Tara Bancroft - Piper Sandl...

Otonomy, Inc. (OTIC) Q3 2020 Earnings Conference Call October 4, 2020 4:20 PM ET Company Participants Robert Uhl - Westwicke Partners David Weber - President, CEO & Director Conference Call Participants Tara Bancroft - Piper Sandler & Co. Oren Livnat - H.C. Wainwright & Co Francoi...

Otonomy (OTIC): Q3 GAAP EPS of -$0.22 beats by $0.02.Revenue of $0.05M (-61.5% Y/Y) misses by $0.01M.FY2020 guidance: Non-GAAP operating expenses of $35M-$38M , GAAP operating expenses of $45M-$48M. Cash equivalents, and short-term investments will be sufficient to fund the company’s o...